SEC Company Response from Mereo BioPharma Group plc (MREO) (CIK 0001719714) (MREO) — Mar 6, 2020
Mereo BioPharma Group plc (MREO) (CIK 0001719714)
Date: March 6, 2020 · CIK: 0001719714 · Accession: 0001193125-20-065264
AI Filing Summary & Sentiment
File numbers found in text: 333-236497
Letter
VIA EDGAR Division of Corporation Finance Re: Mereo BioPharma Group plc Registration Statement on Form F-1 Filed February 18, 2020 File No. 333-236497
Dear Messrs. McCann and Lindsay:
This letter is being furnished on behalf of Mereo BioPharma Group plc (the “Company”) in response to a comment received from the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) by letter, dated March 2, 2020 to Richard Jones, Chief Financial Officer of the Company. The text of the Staff’s comment has been included in this letter below in bold and italics for your convenience. We have also set forth the Company’s response to the Staff’s comment. In addition, on behalf of the Company, we are hereby filing Amendment No. 1 to the Registration Statement on Form F-1 (the “Registration Statement”) with the Commission.
Incorporation of Certain Documents by Reference, page 75
1. We note that you incorporate information by reference into your registration statement. However, to be eligible to incorporate by reference, you must have filed your annual report required under Section 13(a) or Section 15(d) of the Exchange Act for your most recently completed fiscal year. See General Instruction VI.C to Form F-1. Please amend your registration statement to include all disclosure required by Form F-1, or, in the alternative, file your Form 20-F for the fiscal year ended December 31, 2019. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Mayer Brown is a global services provider comprising an association of legal practices that are separate entities including
Mayer Brown LLP (Illinois, USA), Mayer Brown International LLP (England), Mayer Brown (a Hong Kong partnership)
and Tauil & Chequer Advogados (a Brazilian partnership).
March 6, 2020
Response:
The Company acknowledges the Staff’s comment and has amended the Registration Statement to include and not incorporate by reference the disclosure required by Form F-1.
If you have any questions regarding the foregoing, feel free to contact David Bakst at (212) 506-2551. Thank you for your assistance.
Sincerely,
/s/ David S. Bakst
Show Raw Text
CORRESP 1 filename1.htm CORRESP Mayer Brown LLP 1221 Avenue of the Americas New York, New York 10020-1001 Main Tel +1 212 506 2500 Main Fax +1 212 262 1910 www.mayerbrown.com March 6, 2020 VIA EDGAR Joe McCann Courtney Lindsay U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Mereo BioPharma Group plc Registration Statement on Form F-1 Filed February 18, 2020 File No. 333-236497 Dear Messrs. McCann and Lindsay: This letter is being furnished on behalf of Mereo BioPharma Group plc (the “Company”) in response to a comment received from the staff of the Division of Corporation Finance (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) by letter, dated March 2, 2020 to Richard Jones, Chief Financial Officer of the Company. The text of the Staff’s comment has been included in this letter below in bold and italics for your convenience. We have also set forth the Company’s response to the Staff’s comment. In addition, on behalf of the Company, we are hereby filing Amendment No. 1 to the Registration Statement on Form F-1 (the “Registration Statement”) with the Commission. Incorporation of Certain Documents by Reference, page 75 1. We note that you incorporate information by reference into your registration statement. However, to be eligible to incorporate by reference, you must have filed your annual report required under Section 13(a) or Section 15(d) of the Exchange Act for your most recently completed fiscal year. See General Instruction VI.C to Form F-1. Please amend your registration statement to include all disclosure required by Form F-1, or, in the alternative, file your Form 20-F for the fiscal year ended December 31, 2019. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Mayer Brown is a global services provider comprising an association of legal practices that are separate entities including Mayer Brown LLP (Illinois, USA), Mayer Brown International LLP (England), Mayer Brown (a Hong Kong partnership) and Tauil & Chequer Advogados (a Brazilian partnership). March 6, 2020 Response: The Company acknowledges the Staff’s comment and has amended the Registration Statement to include and not incorporate by reference the disclosure required by Form F-1. If you have any questions regarding the foregoing, feel free to contact David Bakst at (212) 506-2551. Thank you for your assistance. Sincerely, /s/ David S. Bakst David S. Bakst Mayer Brown LLP cc: Richard Jones Charles Sermon Denise Scotts-Knight Mereo BioPharma Group plc